Improving Advanced-Line Multiple Myeloma Care: Insights and Real-World Challenges from the EMMY Study

Titouan Cazaubiel et al. 2025

Table S1. Treatments received by patients at each line

	L4 n=786	L5 n=585	L6 n=380	L7 n=231
Glucocorticoids, n (%)	674 (85.8%)	461 (78.8%)	272 (71.6%)	160 (69.3%)
PI, n (%)	363 (46.2%)	258 (44.1%)	167 (43.9%)	86 (37.2%)
Bortezomib	141 (17.9%)	96 (16.4%)	62 (16.3%)	34 (14.7%)
Ixazomib	42 (5.3%)	38 (6.5%)	32 (8.4%)	15 (6.5%)
Carfilzomib	180 (22.9%)	124 (21.2%)	73 (19.2%)	37 (16%)
IMiD, n (%)	346 (44%)	177 (30.3%)	89 (23.4%)	53 (22.9%)
Thalidomide	2 (0.3%)	8 (1.4%)	8 (2.1%)	3 (1.3%)
Lenalidomide	98 (12.5%)	56 (9.6%)	42 (11.1%)	25 (10.8%)
Pomalidomide	246 (31.3%)	114 (19.5%)	39 (10.3%)	25 (10.8%)
Anti-CD38 mAb, n (%)	284 (36.1%)	187 (32%)	86 (22.6%)	34 (14.7%)
Daratumumab	238 (30.3%)	162 (27.7%)	73 (19.2%)	26 (11.3%)
Isatuximab	46 (5.9%)	25 (4.3%)	13 (3.4%)	8 (3.5%)
BCMA-targeted therapies, n (%)	22 (2.8%)	38 (6.5%)	28 (7.4%)	24 (10.4%)
CAR-T-cells	1 (0.1%)	3 (0.5%)	3 (0.8%)	0 (0%)
Belantamab Mafodotin	21 (2.7%)	35 (6%)	25 (6.6%)	24 (10.4%)
Alkylating agents, n (%)	196 (24.9%)	17 (30.3%)	135 (35.5%)	91 (39.4%)
Melphalan	24 (3.1%)	28 (4.8%)	24 (6.3%)	11 (4.8%)
Cyclophosphamide	134 (17%)	103 (17.6%)	58 (15.3%)	38 (16.5%)
Bendamustine	40 (5.1%)	54 (9.2%)	59 (15.5%)	44 (19%)
Others, n (%)	74 (9.2%)	92 (15.7%)	68 (17.9%)	48 (20.8%)

[a] Corresponding author, Titouan Cazaubiel, e-mail: titouan.cazaubiel@gmail.com

Doxorubicine	34 (4.3%)	30 (5.1%)	22 (5.8%)	20 (8.7%)
Etoposide	20 (2.5%)	23 (3.9%)	15 (3.9%)	8 (3.5%)
Venetoclax	21 (2.7%)	28 (4.8%)	28 (7.4%)	11 (4.8%)

BCMA B-cell maturation antigen, CAR chimeric antigen receptor, IMiD immunomodulatory drugs, mAb monoclonal antibodies, PI proteasome inhibitors.


**Figure S1** Class of drug received by patients at each line

Figure S2 Type of regimen and class of drug use in L4 depending on the year of line initiation

A

B

Figure S3 Progression free survival (A) and overall survival (B) in patients with advanced line therapy by treatment line